Download PDF
Thromb Haemost 1996; 75(01): 203-210
DOI: 10.1055/s-0038-1650243
Original Article
Schattauer GmbH Stuttgart

The Antithrombotic Effect of Aurin Tricarboxylic Acid in the Guinea Pig Is not Solely due to Its Interaction with the von Willebrand Factor-GPIb Axis

K Azzam
The Institut des Vaisseaux et du Sang and the Unit 353 INSERM, Paris, France
,
M Cissé-Thiam
The Institut des Vaisseaux et du Sang and the Unit 353 INSERM, Paris, France
,
L Drouet
The Institut des Vaisseaux et du Sang and the Unit 353 INSERM, Paris, France
› Author Affiliations
Further Information

Publication History

Received: 18 January 1995

Accepted after resubmission19 September 1995

Publication Date:
10 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Commercial aurin tricarboxylic acid (ATA) has been reported to interfere specifically with von Willebrand factor-glycoprotein lb (vWF-GPIb) axis. This study was designed to explore the antithrombotic effects of AT A by examining its effects on guinea pig platelet function in vitro, in vivo and ex vivo. In vitro, addition of various concentrations of ATA to platelet-rich guinea pig plasma totally inhibited ristocetin-induced platelet aggregation, as expected. Unexpectedly, however, ATA similarly inhibited the aggregation induced by ADP, PAF, collagen, I-BOP (a thromboxane A2/prostaglandin H2 analogue) and arachidonic acid.

In vivo, the antithrombotic action of ATA was assessed in a model of acute platelet-dependent guinea pig mesenteric artery thrombosis triggered by laser-induced intimal injury. As the thrombotic response of arteries to such injury is a spontaneous cyclic recurrent process, 5 arteries in each animal were consecutively studied for 15 min each after i.v. bolus injection of 5, 7.5 or 10 mg/kg of ATA, which reduced the number of recurrent thrombi per artery in a dose-dependent manner. The highest dose of 10 mg/kg induced maximal inhibition of thrombus formation (72%, p <0.001) 5 min after injection.

Ex vivo, platelet aggregation was assessed in blood samples taken before and after i.v. bolus injection of 10 or 15 mg/kg ATA. Ten mg/kg significantly inhibited collagen-induced aggregation, and 15 mg/kg, the aggregation induced by ristocetin, ADP, PAF, collagen, I-BOP and arachidonic acid.

The results of the in vivo studies confirmed that ATA is an effective antithrombotic agent. In the in vitro and ex vivo studies, ristocetin-induced platelet aggregation confirmed that ATA interacts with the vWF-GPIb axis, and suggests that the final common pathway of the aggregation induced by other agents tested consists of fibrinogen binding to the platelet GPIIb/IIIa receptor. We conclude that ATA interferes with vWF binding to GPIb, that it may interact with fibrinogen binding to GPIIb/IIIa, and that it might possess potent antithrombotic properties in platelet-mediated thrombosis.

 

  • References

  • 1 Meyer D, Obert B, Pietu G, Lavergne JM, Zimmermann TS. Multimeric structure of factor VUI/von Willebrand factor in von Willebrand’s disease. J Lab Clin Med 1980; 95: 590-602
    PubMedGoogle Scholar
  • 2 Kalafatis M, Takahashi Y, Girma JP, Meyer D. Localization of a collagen-interactive domain of human von Willebrand Factor between amino acid residues Gly 911 and Glu 1,365. Blood 1987; 70: 1577-1583
    CrossrefPubMedGoogle Scholar
  • 3 Mohri H, Yoshioka A, Zimmermann TS, Ruggeri ZM. Isolation of von Willebrand Factor domain interacting with glycoprotein lb, heparin and collagen and characterization of its three distinct functional sites. J Bio Chem 1989; 264: 17361-17367
    PubMedGoogle Scholar
  • 4 Fujimura Y, Titani K, Holland LZ, Roberts JR, Kostel P, Ruggeri ZM, Zimmermann TS. A heparin binding domain of human von Willebrand factor. Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. J Biol Chem 1987; 262: 1734-1739
    PubMedGoogle Scholar
  • 5 Fauvel-Lafeve F, Legrand YJ. Binding of plasma von Willebrand by arterial microfibrils. Thromb Haemost 1990; 64: 145-149
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 de Groot PG, Ottentof-Rovers M, van Mourik JA, Sixma JJ. Evidence that the primary binding site of von Willebrand Factor that mediates platelet adhesion on subendothelium is not collagen. J Clin Invest 1988; 82: 65-73
    CrossrefPubMedGoogle Scholar
  • 7 Mohri H, Fujimura Y, Shima M, Yoshioka A, Houghten RA, Ruggeri ZM, Zimmermann TS. Structure of von Willebrand Factor domain interacting with glycoprotein lb. J Biol Chem 1988; 263: 17901-17904
    PubMedGoogle Scholar
  • 8 Girma JP, Kalafatis M, Pietu G, Lavergne JM, Chopek MW, Edgington TS, Meyer D. Mapping of distinct von Willebrand Factor domains interacting with platelet GPIb and GPIIb/IIIa and with collagen using monoclonal antibodies. Blood 1986; 67: 1356-1366
    PubMedGoogle Scholar
  • 9 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand disease and the Bernard Soulier syndrome. J Lab Clin Med 1978 92. 750-764
    PubMedGoogle Scholar
  • 10 Nurden AT, Caen JP. The different glycoprotein abnormalities in throm-basthenic and Bernard-Soulier platelets. Semin Hematol 1979; 16: 234
    PubMedGoogle Scholar
  • 11 Coller BS, Peerschke El, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand Factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand Factor. Blood 1983; 61: 99-111
    PubMedGoogle Scholar
  • 12 Bolhuis PA, Sakariassen KS, Sander HJ, Bouma BN, Sixma JJ. Binding of factor VUI-von Willebrand Factor to subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med 1981; 97: 568-576
    PubMedGoogle Scholar
  • 13 Miller JL, Thiam-Cisse M, Drouet LO. Reduction in thrombus formation by PG-1 F(ab’) 2 an anti guinea pig platelet glycoprotein lb monoclonal antibody. Arteriosclerosis and Thrombosis 1991; 11: 1231-1236
    CrossrefPubMedGoogle Scholar
  • 14 Nichols TC, Bellinger DA, Reddick RL, Read MS, Koch GG, Brinkhous KM, Griggs TR. Role of von Willebrand Factor in arterial thrombosis. Studies in normal and von Willebrand disease pigs. Circulation 1991; 83 suppl IV 56-64
    PubMedGoogle Scholar
  • 15 Turitto VT, Baumgartner HR. Platelet-surface interactions. In: Hemostasis and Thrombosis (2nd ed) Colman RW, Hirsh J, Marder VJ, Salzman EW. eds JB Lippincott Co., Philadelphia; 1987: 555-571
  • 16 Tangelder GJ, Slaaf DW, Arts T, Reneman RS. Wall shear rate in arterioles in vivo: Least estimates from platelet velocity profiles. Am J Physiol 1988; 254: H1059-H1064
    PubMedGoogle Scholar
  • 17 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Heliums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate and is resistant to aspirin. Blood 1988; 71: 1366-1374
    CrossrefPubMedGoogle Scholar
  • 18 Chow TW, Heliums JD, Moake JL, Kroll MH. Shear stress-induced von Willebrand Factor binding to platelet glycoprotein lb initiates calcium influx associated with aggregation. Blood 1992; 80: 113-120
    CrossrefPubMedGoogle Scholar
  • 19 Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hrinda ME, McLntire LV. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand Factor binding to platelets. Blood 1993; 81: 1263-1276
    PubMedGoogle Scholar
  • 20 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Heliums JD. Involvement of large plasma von Willebrand Factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-1461
    CrossrefPubMedGoogle Scholar
  • 21 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Iraki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand Factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-1240
    CrossrefPubMedGoogle Scholar
  • 22 Peterson DM, Stathopoulos NA, Giorgio D, Heliums JD, Moake JL. Shear-induced platelet aggregation requires von Willebrand Factor and platelet membrane glycoproteins lb and Ilb/IIIa. Blood 1987; 69: 625-628
    PubMedGoogle Scholar
  • 23 Howard MA, Firkin BG. Ristocetin, a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-369
    PubMedGoogle Scholar
  • 24 Howard MA, Perkin J, Salem HH, Firkin BG. The agglutination of human platelets by botrocetin: Evidence that botrocetin and ristocetin act at different sites on the factor VIII molecule and platelet membrane. Br J Haematol 1984; 57: 25-35
    CrossrefPubMedGoogle Scholar
  • 25 Fujimoto T, Ohara S, Hawiger J. Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VUI/von Willebrand Factor on human platelets. J Clin Invest 1982; 69: 1212-1222
    CrossrefPubMedGoogle Scholar
  • 26 Phillips MD, Moake JL, Nolasco L, Turner N. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand Factor and platelets. Blood 1988; 72: 1898-1903
    PubMedGoogle Scholar
  • 27 Weinstein M, Vosburgh E, Phillips M, Turner N, Chute-Rose L, Moake J. Isolation from commercial aurin tricarboxylic acid of the most effective polymeric inhibitors of von Willebrand Factor interaction with platelet glycoprotein lb. Comparison with other polyanionic and polyaromatic polymers. Blood 1991; 78: 2291-2298
    PubMedGoogle Scholar
  • 28 Girma JP, Fressinaud E, Christophe O, Rouault C, Obert B, Takahashi Y, Meyer D. Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand Factor and competing with glycoprotein lb. Thromb Haemost 1992; 68: 707-713
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Strony J, Phillips M, Brands D, Moake J, Adelman B. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation 1990; 81: 1106-1114
    CrossrefPubMedGoogle Scholar
  • 30 Kupinski JM, Miller JL. Synthesis by guinea pig megakaryocytes of platelet glycoprotein receptors for fibrinogen and von Willebrand Factor. Thromb Res 1986; 43: 345-352
    CrossrefPubMedGoogle Scholar
  • 31 Kupinski JM, Miller JL. Identification of receptors for fibrinogen and von Willebrand factor mediating aggregation in guinea pig platelets. Thromb Res 1986; 43: 335-344
    CrossrefPubMedGoogle Scholar
  • 32 Dorn GW. Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes. A radioligand binding study of human platelets. J Clin Invest 1989; 84: 1883-1891
    PubMedGoogle Scholar
  • 33 Dorn GW, De Jesus A. Binding of an 125I labeled thromboxane A2/prosta-glandin H2 receptor agonist to baboon platelets. Prostaglandins 1989; 38: 645-653
    CrossrefPubMedGoogle Scholar
  • 34 Morinelli TA, Oatis JE, Okwu AK, Mais DE, Mayeux PR, Masuda A, Knapp DR, Halushka PV. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist. J Pharmacol Exp. Ther 1989; 251: 557-562
    PubMedGoogle Scholar
  • 35 Anderson RR, Parrish JA. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin. Lasers in Surg and Med 1981; 1: 263-276
    PubMedGoogle Scholar
  • 36 Drouet L, Godard B, Gebrane-Younes J, Pignaud G, Chameroy V. In vivo effects of a dye pulsed laser on microcirculation. In: Biology and pathology of platelet-vessel wall interactions Jolles G, Legrand Y, Nurden AT. ed Academic Press; London: 1986: 351-373
  • 37 Haugwitz R. New anti-HIV compounds belonging to aurintricarboxylic acid. US-7431568 1989
    PubMedGoogle Scholar
  • 38 Kawasaki T, Kaku S, Kohinata T, Sakai Y, Taniuchi Y, Kawamura K, Yano S, Takenada T, Fujimura Y. Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelets GPIb, platelet retention, and thrombus formation in vivo. Am J Hematol 1994; 47: 6-15
    CrossrefPubMedGoogle Scholar
  • 39 Zhoazeng GUO, Weinstein MJ, Philips MD, Kroll MH. Mr 6,400 aurintricarboxylic acid directly activates platelets. Thromb Res 1993; 71: 77-88
    CrossrefPubMedGoogle Scholar
  • 40 Weinstein M, Phillips M, Vasburg E, Moake JL. Comparison of aurintricarboxylic acid (ATA) and polystyrene sulfonate as inhibitors of platelet-von Willebrand factor (vWf) interaction. Blood 1990; 76 (Suppl. 01) suppl 1 524 a
    PubMedGoogle Scholar
  • 41 Kinlough-Rathbone RL, Packham MA. Unexpected effects of aurin tricarboxylic acid on human platelets. Thromb and Haemost 1992; 68: 189-193
    PubMedGoogle Scholar
  • 42 George JN, Nurden AT, Phillips DR. Molecular defects that cause abnormalities of platelet-vessel wall interaction. N Engl J Med 1984; 311: 1084-1094
    CrossrefPubMedGoogle Scholar
  • 43 Coller BS, Peerschke El, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins lib and/or Ilia. J Clin Invest 1983; 72: 325-338
    CrossrefPubMedGoogle Scholar
  • 44 Plow EF, McEver RP, Coller BS, Woods VL, Marguerie GA, Ginsberg MH. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor and thrombospondin on thrombin-stimulated platelets. Blood 1985; 66: 724-727
    PubMedGoogle Scholar
  • 45 Wulf E. Wechselwirkungen des Enzyminhibitors Aurintrikarboxylat mit Plasmaproteinen. Acta Biol Med Germ 1979; 38: 125-128
    PubMedGoogle Scholar
  • 46 Bush LR, Shebuski RJ. In vivo model of arterial thrombosis and thrombolysis. FASEB J 1990; 4: 3087-3098
    CrossrefPubMedGoogle Scholar